These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

211 related articles for article (PubMed ID: 39107280)

  • 21. Oncogenic role of HMGA2 in fusion-negative rhabdomyosarcoma cells.
    Ouchi K; Miyachi M; Yagyu S; Kikuchi K; Kuwahara Y; Tsuchiya K; Iehara T; Hosoi H
    Cancer Cell Int; 2020; 20():192. PubMed ID: 32489328
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Piperacetazine Directly Binds to the PAX3::FOXO1 Fusion Protein and Inhibits Its Transcriptional Activity.
    Nakazawa K; Shaw T; Song YK; Kouassi-Brou M; Molotkova A; Tiwari PB; Chou HC; Wen X; Wei JS; Deniz E; Toretsky JA; Keller C; Barr FG; Khan J; Üren A
    Cancer Res Commun; 2023 Oct; 3(10):2030-2043. PubMed ID: 37732905
    [TBL] [Abstract][Full Text] [Related]  

  • 23. JARID2 is a direct target of the PAX3-FOXO1 fusion protein and inhibits myogenic differentiation of rhabdomyosarcoma cells.
    Walters ZS; Villarejo-Balcells B; Olmos D; Buist TW; Missiaglia E; Allen R; Al-Lazikani B; Garrett MD; Blagg J; Shipley J
    Oncogene; 2014 Feb; 33(9):1148-57. PubMed ID: 23435416
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Preclinical Evaluation of the FGFR-Family Inhibitor Futibatinib for Pediatric Rhabdomyosarcoma.
    Wu JT; Cheuk A; Isanogle K; Robinson C; Zhang X; Ceribelli M; Beck E; Shinn P; Klumpp-Thomas C; Wilson KM; McKnight C; Itkin Z; Sotome H; Hirai H; Calleja E; Wacheck V; Gouker B; Peer CJ; Corvalan N; Milewski D; Kim YY; Figg WD; Edmondson EF; Thomas CJ; Difilippantonio S; Wei JS; Khan J
    Cancers (Basel); 2023 Aug; 15(16):. PubMed ID: 37627061
    [TBL] [Abstract][Full Text] [Related]  

  • 25. A method to culture human alveolar rhabdomyosarcoma cell lines as rhabdospheres demonstrates an enrichment in stemness and Notch signaling.
    Slemmons KK; Deel MD; Lin YT; Oristian KM; Kuprasertkul N; Genadry KC; Chen PH; Chi JT; Linardic CM
    Biol Open; 2021 Feb; 10(2):. PubMed ID: 33372065
    [TBL] [Abstract][Full Text] [Related]  

  • 26. The Polycomb group (PcG) protein EZH2 supports the survival of PAX3-FOXO1 alveolar rhabdomyosarcoma by repressing FBXO32 (Atrogin1/MAFbx).
    Ciarapica R; De Salvo M; Carcarino E; Bracaglia G; Adesso L; Leoncini PP; Dall'Agnese A; Walters ZS; Verginelli F; De Sio L; Boldrini R; Inserra A; Bisogno G; Rosolen A; Alaggio R; Ferrari A; Collini P; Locatelli M; Stifani S; Screpanti I; Rutella S; Yu Q; Marquez VE; Shipley J; Valente S; Mai A; Miele L; Puri PL; Locatelli F; Palacios D; Rota R
    Oncogene; 2014 Aug; 33(32):4173-84. PubMed ID: 24213577
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Immunohistochemical detection of PAX-FOXO1 fusion proteins in alveolar rhabdomyosarcoma using breakpoint specific monoclonal antibodies.
    Azorsa DO; Bode PK; Wachtel M; Cheuk ATC; Meltzer PS; Vokuhl C; Camenisch U; Khov HL; Bode B; Schäfer BW; Khan J
    Mod Pathol; 2021 Apr; 34(4):748-757. PubMed ID: 33299109
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Histone Deacetylase 3 Regulates Adipocyte Phenotype at Early Stages of Differentiation.
    Cricrí D; Coppi L; Pedretti S; Mitro N; Caruso D; De Fabiani E; Crestani M
    Int J Mol Sci; 2021 Aug; 22(17):. PubMed ID: 34502211
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Modulating the dose-rate differently affects the responsiveness of human epithelial prostate- and mesenchymal rhabdomyosarcoma-cancer cell line to radiation.
    Petragnano F; Pietrantoni I; Di Nisio V; Fasciani I; Del Fattore A; Capalbo C; Cheleschi S; Tini P; Orelli S; Codenotti S; Mazzei MA; D'Ermo G; Pannitteri G; Tombolini M; De Cesaris P; Riccioli A; Filippini A; Milazzo L; Vulcano F; Fanzani A; Maggio R; Marampon F; Tombolini V
    Int J Radiat Biol; 2020 Jun; 96(6):823-835. PubMed ID: 32149569
    [No Abstract]   [Full Text] [Related]  

  • 30. Heme Oxygenase-1 Controls an HDAC4-miR-206 Pathway of Oxidative Stress in Rhabdomyosarcoma.
    Ciesla M; Marona P; Kozakowska M; Jez M; Seczynska M; Loboda A; Bukowska-Strakova K; Szade A; Walawender M; Kusior M; Stepniewski J; Szade K; Krist B; Yagensky O; Urbanik A; Kazanowska B; Dulak J; Jozkowicz A
    Cancer Res; 2016 Oct; 76(19):5707-5718. PubMed ID: 27488535
    [TBL] [Abstract][Full Text] [Related]  

  • 31. KDM3A/Ets1/MCAM axis promotes growth and metastatic properties in Rhabdomyosarcoma.
    Sobral LM; Sechler M; Parrish JK; McCann TS; Jones KL; Black JC; Jedlicka P
    Genes Cancer; 2020; 11(1-2):53-65. PubMed ID: 32577157
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Targeted inhibition of histone deacetylase leads to suppression of Ewing sarcoma tumor growth through an unappreciated EWS-FLI1/HDAC3/HSP90 signaling axis.
    Ma Y; Baltezor M; Rajewski L; Crow J; Samuel G; Staggs VS; Chastain KM; Toretsky JA; Weir SJ; Godwin AK
    J Mol Med (Berl); 2019 Jul; 97(7):957-972. PubMed ID: 31025088
    [TBL] [Abstract][Full Text] [Related]  

  • 33. The histone deacetylase inhibitor Suberoylanilide Hydroxamic Acid (SAHA) as a therapeutic agent in rhabdomyosarcoma.
    Ghayad SE; Rammal G; Sarkis O; Basma H; Ghamloush F; Fahs A; Karam M; Harajli M; Rabeh W; Mouawad JE; Zalzali H; Saab R
    Cancer Biol Ther; 2019; 20(3):272-283. PubMed ID: 30307360
    [TBL] [Abstract][Full Text] [Related]  

  • 34. PAX3-FOXO1 dictates myogenic reprogramming and rhabdomyosarcoma identity in endothelial progenitors.
    Searcy MB; Larsen RK; Stevens BT; Zhang Y; Jin H; Drummond CJ; Langdon CG; Gadek KE; Vuong K; Reed KB; Garcia MR; Xu B; Kimbrough DW; Adkins GE; Djekidel N; Porter SN; Schreiner PA; Pruett-Miller SM; Abraham BJ; Rehg JE; Hatley ME
    Nat Commun; 2023 Nov; 14(1):7291. PubMed ID: 37968277
    [TBL] [Abstract][Full Text] [Related]  

  • 35. PAX7 is a required target for microRNA-206-induced differentiation of fusion-negative rhabdomyosarcoma.
    Hanna JA; Garcia MR; Go JC; Finkelstein D; Kodali K; Pagala V; Wang X; Peng J; Hatley ME
    Cell Death Dis; 2016 Jun; 7(6):e2256. PubMed ID: 27277678
    [TBL] [Abstract][Full Text] [Related]  

  • 36. CDK4 Amplification Reduces Sensitivity to CDK4/6 Inhibition in Fusion-Positive Rhabdomyosarcoma.
    Olanich ME; Sun W; Hewitt SM; Abdullaev Z; Pack SD; Barr FG
    Clin Cancer Res; 2015 Nov; 21(21):4947-59. PubMed ID: 25810375
    [TBL] [Abstract][Full Text] [Related]  

  • 37. KDM3B inhibitors disrupt the oncogenic activity of PAX3-FOXO1 in fusion-positive rhabdomyosarcoma.
    Kim YY; Gryder BE; Sinniah R; Peach ML; Shern JF; Abdelmaksoud A; Pomella S; Woldemichael GM; Stanton BZ; Milewski D; Barchi JJ; Schneekloth JS; Chari R; Kowalczyk JT; Shenoy SR; Evans JR; Song YK; Wang C; Wen X; Chou HC; Gangalapudi V; Esposito D; Jones J; Procter L; O'Neill M; Jenkins LM; Tarasova NI; Wei JS; McMahon JB; O'Keefe BR; Hawley RG; Khan J
    Nat Commun; 2024 Feb; 15(1):1703. PubMed ID: 38402212
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Down-regulation of HDAC3 inhibits growth of cholangiocarcinoma by inducing apoptosis.
    Zhang M; Yin Y; Dorfman RG; Zou T; Pan Y; Li Y; Wang Y; Zhou Q; Zhou L; Kong B; Friess H; Zhang J; Zhao S; Wang L; Zou X
    Oncotarget; 2017 Nov; 8(59):99402-99413. PubMed ID: 29245911
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Functional-genetic dissection of HDAC dependencies in mouse lymphoid and myeloid malignancies.
    Matthews GM; Mehdipour P; Cluse LA; Falkenberg KJ; Wang E; Roth M; Santoro F; Vidacs E; Stanley K; House CM; Rusche JR; Vakoc CR; Zuber J; Minucci S; Johnstone RW
    Blood; 2015 Nov; 126(21):2392-403. PubMed ID: 26447190
    [TBL] [Abstract][Full Text] [Related]  

  • 40. FAK Signaling in Rhabdomyosarcoma.
    Perrone C; Pomella S; Cassandri M; Braghini MR; Pezzella M; Locatelli F; Rota R
    Int J Mol Sci; 2020 Nov; 21(22):. PubMed ID: 33182556
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 11.